Search

Your search keyword '"Morgan, Robert D."' showing total 714 results
Start Over Author "Morgan, Robert D."
714 results on '"Morgan, Robert D."'

14. Reception to and Efficacy of a Serious Video Game for Correctional Intervention: Project Choices.

Author

Diehl, Keegan J., Morgan, Robert D., King, Christopher M., Ingram, Paul B., and Mitchell, Cooper

Subjects
VIDEO games, MEDICAL rehabilitation, PROBLEM solving, PROBATION, PILOT projects
Abstract

Project Choices (PC), a newly developed videogame for correctional intervention, consists of realistic decision-making scenarios and cognitive behavioral skills feedback. A pilot study investigated PC engagement and immersion by employing a cross-over design with a sample of 24 men on probation remanded to residential treatment. The study also examined effects of gameplay on criminogenic thinking, self-perceived criminogenic risk, and social problem-solving. As hypothesized, relative to a leisure video game (Tetris), participants generally appeared comparably engaged by and immersed in PC. Most hypothesized effects of PC on treatment-relevant outcomes were not statistically significant; however, PC contributed to moderate to large treatment effects across most outcomes of interest. Although results are promising, PC requires further validation to determine whether it could serve as a useful adjunctive tool for practitioners hoping to further reach and engage corrections clients in criminogenic risk-reduction services. Future research directions for technology like PC are numerous and encouraged. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom.

Author

Leung, Elaine Y. L., Nicum, Shibani, Morrison, Jo, Brenton, James D., Funingana, Ionut-Gabriel, Morgan, Robert D., Ghaem-Maghami, Sadaf, Miles, Tracie, Manchanda, Ranjit, Bowen, Rebecca, Andreou, Adrian, Loughborough, Will, Freeman, Susan, Gajjar, Ketan, Coleridge, Sarah, Jimenez-Linan, Mercedes, Balega, Janos, Frost, Jonathan, Keightley, Amy, and Wallis, Yvonne

Published
2024
Full Text
View/download PDF

18. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial

Author

Murphy, Alexander D, primary, Porter, Catharine, additional, White, Ann, additional, Irving, Alys, additional, Adams, Richard, additional, Ray, Ruby, additional, Casbard, Angela, additional, Mahmood, Reem D, additional, Karanth, Suman, additional, Zhou, Cong, additional, Pugh, Julia, additional, Wheeler, Chelsey, additional, Roberts, Victoria, additional, Arnetoli, Giorgio, additional, Salih, Zena, additional, Hasan, Jurjees, additional, Mitchell, Claire, additional, Morgan, Robert D, additional, Clamp, Andrew R, additional, and Jayson, Gordon C, additional

Published
2024
Full Text
View/download PDF

20. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Author

Morgan, Robert D, McNeish, Iain A, Cook, Adrian D, James, Elizabeth C, Lord, Rosemary, Dark, Graham, Glasspool, Rosalind M, Krell, Jonathan, Parkinson, Christine, Poole, Christopher J, Hall, Marcia, Gallardo-Rincón, Dolores, Lockley, Michelle, Essapen, Sharadah, Summers, Jeff, Anand, Anjana, Zachariah, Abel, Williams, Sarah, Jones, Rachel, Scatchard, Kate, Walther, Axel, Kim, Jae-Weon, Sundar, Sudha, Jayson, Gordon C, Ledermann, Jonathan A, and Clamp, Andrew R

Published
2021
Full Text
View/download PDF

25. Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study

Author

Mahmood, Reem D., Shaw, Danielle, Descamps, Tine, Zhou, Cong, Morgan, Robert D., Mullamitha, Saifee, Saunders, Mark, Mescallado, Nerissa, Backen, Alison, Morris, Karen, Little, Ross A., Cheung, Susan, Watson, Yvonne, O’Connor, James P. B., Jackson, Alan, Parker, Geoff J. M., Dive, Caroline, and Jayson, Gordon C.

Published
2021
Full Text
View/download PDF

27. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

Author

Flaum, Nicola, Morgan, Robert D., Burghel, George J., Bulman, Michael, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Badea, Doina, Moon, Sarah, Hogg, Martin, Hadjiyiannakis, Dennis, Clancy, Tara, Schlecht, Helene, Woodward, Emma R., Crosbie, Emma J., Edmondson, Richard J., Wallace, Andrew J., Jayson, Gordon C., Lalloo, Fiona I., Harkness, Elaine F., and Evans, D. Gareth R.

Published
2020
Full Text
View/download PDF

29. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe

Author

Javed, Muhammad Ahsan, Beyer, Georg, Le, Nha, Vinci, Alessio, Wong, Helen, Palmer, Daniel, Morgan, Robert D., Lamarca, Angela, Hubner, Richard A., Valle, Juan W., Alam, Salma, Chowdhury, Sumsur, Ma, Yuk Ting, Archibugi, Livia, Capurso, Gabriele, Maisonneuve, Patrick, Neesse, Albrecht, Sund, Malin, Schober, Marvin, and Krug, Sebastian

Published
2019
Full Text
View/download PDF

32. Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

35. Data from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

37. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

Author

Nelson, Louisa, Tighe, Anthony, Golder, Anya, Littler, Samantha, Bakker, Bjorn, Moralli, Daniela, Murtuza Baker, Syed, Donaldson, Ian J., Spierings, Diana C. J., Wardenaar, René, Neale, Bethanie, Burghel, George J., Winter-Roach, Brett, Edmondson, Richard, Clamp, Andrew R., Jayson, Gordon C., Desai, Sudha, Green, Catherine M., Hayes, Andy, Foijer, Floris, Morgan, Robert D., and Taylor, Stephen S.

Published
2020
Full Text
View/download PDF

39. Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Author

Morgan, Robert D., Burghel, George J., Schlecht, Helene, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Salih, Zena, Shaw, Joseph, Desai, Sudha, Jayson, Gordon C., Woodward, Emma R., and Evans, D. Gareth R.

Subjects
*GENETIC mutation, *SEQUENCE analysis, *SPECIALTY hospitals, *DNA, *BRCA genes, *OVARIAN epithelial cancer, *AGE distribution, *GENETIC testing, *MOLECULAR pathology, *CANCER patients, *CANCER treatment, *STEM cells, *DESCRIPTIVE statistics, *RESEARCH funding, *NUCLEIC acid amplification techniques
Abstract

Simple Summary: Approximately 10–15% of patients with epithelial ovarian cancer have an inherited (germline) BRCA1 or BRCA2 mutation. Following a diagnosis of epithelial ovarian cancer, patients are routinely tested for germline and/or somatic (tumour) BRCA1/2 mutations. Our study shows that if germline BRCA1/2 testing is only performed for patients with a positive tumour BRCA1/2 test result, and tumour testing is performed using Myriad's myChoice® companion diagnostic, a proportion of germline BRCA1/2 large rearrangements could be missed. If paired germline-tumour DNA testing is not possible for all patients, our data shows that it would be appropriate to test all patients with epithelial ovarian cancer aged < 79 years old for germline BRCA1/2 mutations, regardless of the tumour BRCA1/2 result, whilst only needing to test patients aged ≥ 80 years old for a germline BRCA1/2 mutation if they have a positive tumour BRCA1/2 result. Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation sequencing (NGS)-based myChoice® companion diagnostic (CDx; Myriad Genetics, Inc.). Germline BRCA1/2 testing was performed in the North West Genomic Laboratory Hub using NGS and multiplex ligation-dependent probe amplification. Between 11 April 2021 and 11 October 2023, 382 patients were successfully tested for tumour BRCA1 and BRCA2 variants. Of these, 367 (96.1%) patients were tested for germline BRCA1/2 variants. In those patients who underwent tumour and germline testing, 15.3% (56/367) had a BRCA1/2 pathogenic variant (36 germline and 20 somatic). All germline BRCA1/2 pathogenic small sequencing variants were detected in tumour DNA. By contrast, 3 out of 8 germline BRCA1/2 pathogenic large rearrangements were not reported in tumour DNA. The overall concordance of germline BRCA1/2 pathogenic variants detected in germline and tumour DNA was clinically acceptable at 91.7% (33/36). The myChoice® CDx was able to detect most germline BRCA1/2 pathogenic variants in tumour DNA, although a proportion of pathogenic large rearrangements were not reported. If Myriad's myChoice® CDx is used for tumour BRCA1/2 testing, our data supports a testing strategy of germline and tumour BRCA1/2 testing in all patients diagnosed with epithelial ovarian cancer aged < 79 years old, with germline BRCA1/2 testing only necessary for patients aged ≥ 80 years old with a tumour BRCA1/2 pathogenic variant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

Author

Morgan, Robert D, primary, Clamp, Andrew R, additional, Barnes, Bethany M, additional, Timms, Kirsten, additional, Schlecht, Helene, additional, Yarram-Smith, Laura, additional, Wallis, Yvonne, additional, Valganon-Petrizan, Mikel, additional, MacMahon, Suzanne, additional, White, Rhian, additional, Morgan, Sian, additional, McKenna, Sarah, additional, Hudson, Emma, additional, Tookman, Laura, additional, George, Angela, additional, Manchanda, Ranjit, additional, Sundar, Sudha S, additional, Nicum, Shibani, additional, Brenton, James D, additional, Kristeleit, Rebecca S, additional, Banerjee, Susana, additional, McNeish, Iain A, additional, Ledermann, Jonathan A, additional, Taylor, Stephen S, additional, Evans, D Gareth R, additional, and Jayson, Gordon C, additional

Published
2023
Full Text
View/download PDF

45. Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.

Author

Morgan, Robert D., Burghel, George J., Flaum, Nicola, Bulman, Michael, Smith, Philip, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire, Salih, Zena, Woodward, Emma R., Lalloo, Fiona, Shaw, Joseph, Desai, Sudha, Crosbie, Emma J., Edmondson, Richard J., Schlecht, Helene, Wallace, Andrew J., Jayson, Gordon C., and Evans, Gareth R.

Subjects
BREAST, OVARIAN epithelial cancer, TUMORS, NUCLEOTIDE sequencing, CLINICAL trials, DNA
Published
2023
Full Text
View/download PDF

46. Tried and True? A Psychometric Evaluation of the Psychological Inventory of Criminal Thinking Styles-Short Form.

Author

Scanlon, Faith, Lester, Michael E., Brace, Travis, Batastini, Ashley B., and Morgan, Robert D.

Subjects
CRIME & psychology, THOUGHT & thinking, CORRECTIONAL institutions, PRISON psychology, RESEARCH evaluation, CRIMINAL psychology, RESEARCH methodology evaluation, RESEARCH methodology, CRIMINALS, DISCRIMINANT analysis, PSYCHOMETRICS, CRONBACH'S alpha, QUESTIONNAIRES, FACTOR analysis, RESIDENTIAL care, DESCRIPTIVE statistics, PROBATION
Abstract

The Psychological Inventory of Criminal Thinking Styles-Short Form (PICTS-SF) is an abbreviated 35-item version of the PICTS, a measure of cognitions that support a criminal lifestyle. Despite use in research and clinical work, the PICTS-SF's psychometric properties have not been tested. Using two archival datasets, we analyzed the PICTS-SF's reliability and structural validity in multiply imputed data from adult males and females on probation in a residential treatment facility (n = 514). We also tested the PICTS-SF's reliability and discriminant and postdictive validities among adult males in administrative segregation in prison (n = 95). We found evidence for the PICTS-SF's internal consistency (α and ω ≥.89), structural validity (CFI =.90, RMSEA =.05), discriminant validity (.22 ≤ r ≤.39), and postdictive validity for receiving disciplinary infractions (incident rate ratio = 1.04). These results support the PICTS-SF's use in research, and qualified use in clinical applications. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., additional, White, Daniel J., additional, Price, Marcus, additional, Burghel, George J., additional, Ryder, W. David J., additional, Mahmood, Reem D., additional, Murphy, Alexander D., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Wheeler, Chelsey, additional, Buckley, Emma, additional, Truelove, Joanna, additional, King, Georgia, additional, Ainaoui, Yasmina, additional, Bhaskar, Sanjeev S., additional, Shaw, Joseph, additional, Evans, D. Gareth R., additional, Kilerci, Bedirhan, additional, Pearce, Simon P., additional, Brady, Gerard, additional, Dive, Caroline, additional, O'Connor, James P.B., additional, Wallace, Andrew J., additional, Rothwell, Dominic G., additional, Edmondson, Richard J., additional, and Jayson, Gordon C., additional

Published
2023
Full Text
View/download PDF

48. Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?

Author

Morgan, Robert D., primary, Burghel, George J., additional, Flaum, Nicola, additional, Bulman, Michael, additional, Smith, Philip, additional, Clamp, Andrew R., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Woodward, Emma R., additional, Lalloo, Fiona, additional, Crosbie, Emma J., additional, Edmondson, Richard J., additional, Schlecht, Helene, additional, Jayson, Gordon C., additional, and Evans, D. Gareth R., additional

Published
2023
Full Text
View/download PDF

49. On the High-Temperature Oxidation of a Niobium-Bearing High Nickel-Chromium Alloy: Microstructural Evolution and Implications on Oxidation Mechanisms

Author

Shu, Shipeng, primary, Baik, Sung-Il, additional, Kazemzadeh-Atoufi, Maryam, additional, Hu, Xiaobing, additional, Liu, Tao, additional, Shang, Anyu, additional, Davis, Mark, additional, Dhingra, Sandeep, additional, Morgan, Robert D., additional, Voorhees, Peter, additional, and Seidman, David N., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results